Senti Biosciences, Inc.
SNTI
Rank in Stocks
#30535
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit... Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Share Price
$0.1588
Last synced: 2026-11-09
Market Cap
$4.95M
Change (1 day)
-0.75%
Change (1 year)
-91.32%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Senti Biosciences, Inc. (SNTI)
Category
Healthcare
Operating Margin for Senti Biosciences, Inc. (SNTI)
Operating Margin as of November 2026 TTM: -102,761.82%
According to Senti Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -102,761.82%. At the end of 2025 the company had an operating margin of -289,668.18%.
Operating Margin history for Senti Biosciences, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -102,761.82% | -64.52% |
| 2025 | -289,668.18% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -4,687.92% | 148.12% |
| 2022 | -1,889.35% | 7.02% |
| 2021 | -1,765.43% | -71.83% |
| 2020 | -6,267.51% | -75.54% |
| 2019 | -25,625.88% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Senti Biosciences, Inc.'s operating margin
What is Senti Biosciences, Inc.'s operating margin?
Senti Biosciences, Inc.'s operating margin is -102,761.82%, as of Nov 2026.
What was Senti Biosciences, Inc.'s operating margin in 2025?
In 2025, Senti Biosciences, Inc.'s operating margin was -289,668.18%, compared with 0.00% in 2024.
How has Senti Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Senti Biosciences, Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2025 (-289,668.18%).
How does Senti Biosciences, Inc.'s operating margin compare with similar companies?
Senti Biosciences, Inc.'s operating margin (-102,761.82%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.